

# Chandramouli Nagarajan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/361407/publications.pdf>

Version: 2024-02-01

31  
papers

302  
citations

1478505

6  
h-index

888059

17  
g-index

32  
all docs

32  
docs citations

32  
times ranked

597  
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of medium cutoff dialyzers in patients with multiple myeloma and acute kidney injury requiring hemodialysis: A systematic review. <i>Seminars in Dialysis</i> , 2023, 36, 12-17.	1.3	1
2	Treatment outcomes of T and natural killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. <i>Cancer Reports</i> , 2022, , e1552.	1.4	2
3	MO114: Incidence and Spectrum of Biopsy-Proven Dysproteinemic Kidney Diseases: A Single-Centre Experience. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
4	Current and future perspectives of maintenance therapy in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 225-233.	0.8	1
5	BCMA-targeting approaches for treatment of multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 28-36.	0.8	4
6	Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 669288.	2.4	20
7	High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 143.	6.2	17
8	A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). <i>Blood Cancer Journal</i> , 2021, 11, 150.	6.2	2
9	DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. <i>Molecular Cancer</i> , 2021, 20, 134.	19.2	9
10	Lambda light chain crystalline proximal tubulopathy with probable light chain cast nephropathy and clonal plasma cell infiltrate – uncommon manifestations of a rare form of multiple myeloma. <i>Journal of Nephropathology</i> , 2021, 10, e08-e08.	0.2	1
11	No association between <i>ECSIT</i> germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma. <i>Haematologica</i> , 2021, 106, 1737-1739.	3.5	0
12	Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA). <i>Blood</i> , 2021, 138, 2532-2532.	1.4	0
13	Ambiguous Diagnosis of Nodal T-Cell Lymphomas with T-Follicular Helper (TFH) Phenotype and Hodgkin Lymphoma - a Multicenter Pilot Study. <i>Blood</i> , 2021, 138, 1403-1403.	1.4	0
14	Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. <i>Leukemia and Lymphoma</i> , 2020, 61, 225-227.	1.3	8
15	Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). <i>Nutrition</i> , 2020, 79-80, 111017.	2.4	190
16	Pleural plasmacytomas – the role of radiotherapy. <i>British Journal of Haematology</i> , 2020, 190, e160-e162.	2.5	3
17	An unusual cause of renal tubular dysfunction in multiple myeloma. <i>International Urology and Nephrology</i> , 2020, 52, 1603-1605.	1.4	2
18	Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 1759.	3.7	2

#	ARTICLE	IF	CITATIONS
19	Mobilization kinetics of peripheral blood stem cells with rescue plerixafor “ real-world experience from a single center. <i>Leukemia and Lymphoma</i> , 2020, 61, 1740-1743.	1.3	0
20	Surgical management of invasive fungal infections in adult leukemia patients: experience from a large tertiary center in Southeast-Asia. <i>Blood Science</i> , 2020, 2, 59-65.	0.9	0
21	Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. <i>Minerva Medica</i> , 2020, 111, 443-454.	0.9	2
22	Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN). <i>Blood</i> , 2020, 136, 21-21.	1.4	1
23	Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide. <i>Blood</i> , 2020, 136, 25-26.	1.4	0
24	Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)“a trial by the Asian Myeloma Network. <i>Blood Cancer Journal</i> , 2019, 9, 83.	6.2	9
25	Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e470-e477.	0.4	3
26	Delayed diagnosis of Shwachman diamond syndrome with short telomeres and a review of cases in Asia. <i>Leukemia Research Reports</i> , 2018, 9, 54-57.	0.4	6
27	The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2336-2341.	1.3	12
28	Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases. <i>Blood</i> , 2018, 132, 2885-2885.	1.4	0
29	Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas. <i>Blood</i> , 2018, 132, 4165-4165.	1.4	1
30	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. <i>Singapore Medical Journal</i> , 2017, 58, 55-71.	0.6	6
31	Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort. <i>Blood</i> , 2016, 128, 1871-1871.	1.4	0